



Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065

Patent Department

Facsimile Cover Sheet

TODAY'S DATE: April 6, 2007

PLEASE DELIVER THE FOLLOWING MESSAGE TO:

Name: Barbara A. Campbell

Fax number: (571) 270-9841

Group number: TBD

THIS MESSAGE IS FROM:

Name: David Rubin

Phone No.: (732) 594-2675

Mail Location: RY60-30

Fax No.: (732) 594-4720

RE: Applicants: Yang et al.

Case No.: 21556YP

Serial No.: 10/10/586,765

Filed: July 20, 2006

Title: 2,6-Disubstituted Piperidines as Modulators of Chemokine Receptor Activity

NUMBER OF PAGES BEING TRANSMITTED (INCLUDING COVER): 4
Second Preliminary Amendment, attached.

**IF YOU DO NOT RECEIVE ALL OF THE PAGES,
PLEASE CALL (732) 594-1251**

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile
transmitted to the Patent and Trademark Office on the
date shown below:

Christine M. Dona

Type or print name of person signing certification

Christine M. Dona
Signature

April 6, 2007

Date

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Yang *et al.*

Serial No.: 10/586,765 Case No.: 21556YP

Filed: July 20, 2006

For: 2,6-Disubstituted Piperidines as Modulators of Chemokine
Receptor Activity

Art Unit:
TBD
Examiner:
TBD.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**Response to Notification to Comply with Requirements for Patent Applications Containing
Nucleotide and/or Amino Acid Sequence Disclosures**


Sir:

This paper is responsive to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures ("Notification") mailed April 3, 2007.

The referenced patent application relates solely to small molecule chemical compounds, and contains no disclosure or claims relating to nucleotide and/or amino acid sequences. Therefore, applicants respectfully point out that no sequence listing is required in this application.

Applicants respectfully request withdrawal of the Notification.

Respectfully submitted,

By: 

David A. Rubin
Registration Number 40,314
Attorney for Applicants

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-2675

Date: April 6, 2007



UNITED STATES PATENT AND TRADEMARK OFFICE

 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/586,765	Lihu Yang	21556YP

 210
 MERCK AND CO., INC
 P O BOX 2000
 RAHWAY, NJ 07065-0907

INTERNATIONAL APPLICATION NO.	
PCT/US05/00770	
I.A. FILING DATE	PRIORITY DATE
01/14/2005	01/20/2004

CONFIRMATION NO. 1592

371 FORMALITIES LETTER

OC000000023205729

Date Mailed: 04/03/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Page 2 of 2

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/586,765	PCT/US05/00770	21556YP

FORM PCT/DO/EO/922 (371 Formalities Notice)